PAI
CRSP icon

Pittenger & Anderson Inc’s CRISPR Therapeutics CRSP Stock Holding History

Pittenger & Anderson Inc’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,325
Closed -$63K – 526
2026
Q1 		$63K Hold
1,325
– – ﹤0.01% 298
2025
Q4 		$69.5K Buy
+1,325
New +$79.4K ﹤0.01% 289
2021
Q4 		– Sell
-36
Closed -$4K – 459
2021
Q3 		$4K Buy
36
+11
+44% +$1.38K ﹤0.01% 399
2021
Q2 		$4K Buy
25
+8
+47% +$973 ﹤0.01% 365
2021
Q1 		$2K Hold
17
– – ﹤0.01% 373
2020
Q4 		$3K Buy
17
+6
+55% +$709 ﹤0.01% 344
2020
Q3 		$1K Buy
+11
New +$976 ﹤0.01% 355

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pittenger & Anderson Inc's CRSP Position: Q2 2026 in Review

Pittenger & Anderson Inc sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 1,325 shares — an estimated $63K sold.

Pittenger & Anderson Inc first reported a position in CRSP in Q3 2020 and held it in 7 quarters. The position peaked at $69.5K in Q4 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Pittenger & Anderson Inc reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Pittenger & Anderson Inc sold 1,325 CRISPR Therapeutics shares in Q2 2026, an estimated $63K.
  • Pittenger & Anderson Inc first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 7 quarters.
  • Pittenger & Anderson Inc's CRISPR Therapeutics position peaked at $69.5K in Q4 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Pittenger & Anderson Inc's 13F filing for Q2 2026, filed 27 Jul 2026.